GW Henssler & Associates Ltd. Lowers Stake in Gilead Sciences, Inc. $GILD

Key Points

• GW Henssler & Associates Ltd. has significantly reduced its stake by 98.2% in Gilead Sciences, leaving it with only 3,382 shares after selling 188,811 shares during the first quarter.
• Several institutional investors made moves in Gilead Sciences during the same period, with Activest Wealth Management increasing its holdings by 2,837.5%, showcasing heightened interest in the biopharmaceutical company.
• Gilead Sciences reported earnings of $2.01 per share for the last quarter, surpassing estimates and setting guidance for 2025 at 7.950-8.250 EPS.

GW Henssler & Associates Ltd. cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 98.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,382 shares of the biopharmaceutical company's stock after selling 188,811 shares during the quarter. GW Henssler & Associates Ltd.'s holdings in Gilead Sciences were worth $379,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the stock. Redwood Financial Network Corp increased its holdings in Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after acquiring an additional 98 shares during the period. Argentarii LLC increased its holdings in Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock worth $380,000 after acquiring an additional 99 shares during the period. Peak Financial Advisors LLC increased its holdings in Gilead Sciences by 1.7% during the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock worth $677,000 after acquiring an additional 100 shares during the period. Perkins Coie Trust Co increased its holdings in Gilead Sciences by 2.6% during the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock worth $435,000 after acquiring an additional 100 shares during the period. Finally, Investment Research & Advisory Group Inc. increased its holdings in Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on GILD shares. Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a report on Friday, August 8th. UBS Group upped their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 19th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target for the company in a research note on Friday, July 25th. Finally, Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price target for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $115.39.

Gilead Sciences Trading Up 2.0%

Shares of GILD stock traded up $2.28 on Friday, hitting $115.05. 6,953,644 shares of the company's stock traded hands, compared to its average volume of 5,536,983. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a one year low of $78.26 and a one year high of $121.83. The company's fifty day simple moving average is $113.59 and its 200 day simple moving average is $109.89. The stock has a market capitalization of $142.76 billion, a price-to-earnings ratio of 22.92, a P/E/G ratio of 0.76 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be given a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences's dividend payout ratio is presently 62.95%.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director owned 8,920 shares of the company's stock, valued at $978,880.80. This represents a 35.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 82,000 shares of company stock worth $9,371,330. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.